Avascular osteonecrosis of femoral head causes severe musculoskeletal disability. There is not standard treatment to cure avascular osteonecrosis. Recently, cell therapy using bone marrow stromal cells has begun for this disease.
Introduction
Avascular osteonecrosis of the femoral head occurs in patients in their 20s to 40s, causing severe musculoskeletal disability. This disease is idiopathic and is secondary to diseases and treatments, such as dislocation and fracture of the femoral head, sickle cell anemia, highdose steroid therapy, and alcohol. High-dose steroid therapy particularly causes osteonecrosis in a dose dependent manner 1 which causes severe problems clinical. If insufficient treatment is administered, the hip joint, especially the femoral head, will collapse ( Figure 1 ). Joint replacement surgery is rescue treatment for such collapse, however, younger patients will require multiple revision surgeries. For younger patients, joint salvage procedures seem to promise a better prognosis, but there are many difficult problems for treating this disease. Recently, cell therapy using bone marrow stromal cells has begun for this disease.
Number of bone marrow stromal cells decrease around osteonecrotic lesion
A necrotic lesion lacks viable cells, because of the interruption of blood flow. The number of bone marrow stromal cells is decreased in steroid-induced osteonecrosis, not only in the necrotic lesion, but also its surroundings 2, 3 . The osteogenic differentiation ability of mesenchymal stem cells is also altered in osteonecrosis patients 4 . The adipogenic ability of bone marrow cells is elevated in steroidinduced osteonecrosis patients2), 5 . These results suggest that supplying osteogenic cells to necrotic lesions is necessary to cure osteonecrosis.
Mesenchymal stem cells as cell therapy
Mesenchymal stem cells (MSCs) represent a stem cell population in adult tissues that can be isolated and expanded in extra vivo culture, and differentiate into mesenchymal and nonmesenchymal tissues 6 . It is reported that the transplantation of MSCs to an environment enabling them to differentiate into bonelineage cells, is a promising procedure to treat several pathological osseous conditions, including avascular necrosis of bone 7, 8. A simple procedure to supply such cells may be the core decompression technique 9 the main purpose of which is to reduce pressure on necrotic lesions. Some cells may be induced to necrotic lesions from a penetrating hole. This core decompression technique is useful for early stage osteonecrosis 9 .
Concentrated bone marrow transplantation therapy for osteonecrosis
Although MSCs exist in adults and are rich in bone marrow, the fraction of MSC is too small 10 . Hernigue found that bone formation activity depended on the fraction of MSC in bone marrow 11 . He therefore considered that concentrated bone marrow is needed 11 . He concentrated MSC from 150ml bone marrow to 30ml by centrifugatiion 12 . Combined with core decompression surgery, he transplanted this concentrated bone marrow in to the necrotic lesion. As a result, 59% of cases became radiographically stable and 8% were completely cured 12 . Gangji investigated this procedure in a prospective controlled doubleblind study, and concluded it to be useful 13,14. Concentrated bone marrow transplantation can be combined with surgery, such as osteotomy and artificial bone graft 15 . The advantage of concentrated bone marrow transplantation therapy is its low cost, easy technique and low risk for infection or transformation (Table 1) . This low-risk cell therapy may boost the effect of existing therapy.
Extra vivo cultured MSC transplantation
The fraction of MSCs in bone marrow differs among individuals and the technique of aspiration. Hernigou pointed out this issue to explain the different results between each case 12 (Table 1) . To reduce the difference between individuals and techniques, extra vivo culture is useful. About 107 mononuclear cells can be prepared from 10ml bone marrow during two-week culture 15 , suggesting that a huge number of MSCs can be prepared by extra vivo culture. Kawate cultured MSCs with beta-tricalcium phosphate (β-TCP) and transplanted with free vascularlized fibula for two cases of severe osteonecrosis 16 . Muller cultured MSCs under low oxygen tension 17 . Differentiation to bone and revascularization are expected under low oxygen conditiona 17 . Not only for increasing cell numbers, tissue engineering and manipulation may be a benefit of extra vivo culture, however, the cost of extra vivo culture is too high. In Japan, the construction of a cell processing center for extra vivo culture costs $ 30 billion, with $ 1 billion for maintenance per year. Huge expansion may have a risk of cell transformation 18 and genome instability 15 . Strict quality control is needed for extra vivo culture. 
